BillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference TranscriptSeeking Alpha • Wednesday
BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/05/26
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue GuidanceGlobeNewsWire • 11/04/26
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take ShareSeeking Alpha • 10/29/26
BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/28/26
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire • 10/14/26
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP CredentialsSeeking Alpha • 10/13/26
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsGlobeNewsWire • 10/07/26
BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 MillionThe Motley Fool • 09/17/26
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare ConferencePRNewsWire • 09/02/26
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of OriginPRNewsWire • 09/01/26
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive ConditionsPRNewsWire • 08/18/26
BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/06/26
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue GuidanceGlobeNewsWire • 08/05/26
Read Between These Lines As Eli Lilly, Hot IPO And More Face Key TestInvestors Business Daily • 08/03/26